JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldschmidt, J. E.
Right arrow Articles by Tallarida, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldschmidt, J. E.
Right arrow Articles by Tallarida, R. J.

Pharmacological evidence that captopril possesses an endothelium- mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor

JE Goldschmidt and RJ Tallarida

Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania.

Captopril, an angiotensin-converting enzyme inhibitor, reportedly can scavenge superoxide anion (O2-), a property attributed to its sulfhydryl group. The present investigation, using rabbit aortic rings precontracted with either norepinephrine or clonidine, was designed to determine whether captopril possesses an endothelium-dependent component of vasodilation related to its ability to protect endothelium- derived relaxing factor (EDRF) from superoxide-mediated destruction. Also studied were enalaprilat, a nonsulfhydryl angiotensin-converting enzyme-inhibitor, superoxide dismutase, and the sulfhydryl compounds glutathione (GSH), N-2-mercaptopropionylglycine (MPG) and N- acetylcysteine (NAC). Captopril, but not enalaprilat, caused dose- dependent relaxations in preconstricted aortic rings containing an intact endothelium. Rings denuded of endothelium were unresponsive to any dose of captopril. Captopril's vasodilation was not related to prostaglandin influence but was associated with an increase in cyclic GMP. Superoxide dismutase, GSH, MPG and NAC also produced endothelium- dependent relaxations similar to captopril. It was also demonstrated that endothelium-dependent relaxations to acetylcholine were enhanced by captopril, GSH, MPG and NAC but not by enalaprilat. In another set of experiments, the ability of captopril to inhibit superoxide-mediated inactivation of EDRF was examined. Pyrogallol, a potent generator of O2- , and superoxide dismutase, a scavenger of O2-, were used as a basis for comparing a possible scavenging effect of captopril. In preconstricted rings, pyrogallol elicited endothelium-dependent contractions that were attenuated by both captopril and superoxide dismutase. Similar effects were found with GSH, MPG and NAC but not with enalaprilat. These results suggest that captopril's endothelium- dependent vasodilation is due to its sulfhydryl group and the ability of the latter to scavenge O2-, thereby protecting EDRF.

Volume 257, Issue 3, pp. 1136-1145, 06/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
HypertensionHome page
H. Sumino, T. Nakamura, T. Kanda, K. Sato, T. Sakamaki, T. Takahashi, Y. Saito, J. Hoshino, T. Kurashina, and R. Nagai
Effect of Enalapril on Exhaled Nitric Oxide in Normotensive and Hypertensive Subjects
Hypertension, December 1, 2000; 36(6): 934 - 940.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Greenberg, G. Chemin, I. Shapira, J. George, Y. Wollman, S. Laniado, and G. Keren
Captopril and L-Arginine Have a Synergistic Cardioprotective Effect in Ischemic-Reperfusion Injury in the Isolated Rat Heart
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 281 - 290.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Gurevitch, D. Pevni, I. Frolkis, M. Matsa, Y. Paz, R. Mohr, and V. Yakirevich
Captopril in Cardioplegia and Reperfusion: Protective Effects on the Ischemic Heart
Ann. Thorac. Surg., March 1, 1997; 63(3): 627 - 633.
[Abstract] [Full Text]


Home page
HypertensionHome page
H. Iwatsubo, M. Nagano, T. Sakai, K. Kumamoto, R. Morita, J. Higaki, T. Ogihara, and T. Hata
Converting Enzyme Inhibitor Improves Forearm Reactive Hyperemia in Essential Hypertension
Hypertension, January 1, 1997; 29(1): 286 - 290.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Hirata, H. Hayakawa, M. Kakoki, A. Tojo, E. Suzuki, K. Kimura, A. Goto, K. Kikuchi, T. Nagano, M. Hirobe, et al.
Nitric Oxide Release From Kidneys of Hypertensive Rats Treated With Imidapril
Hypertension, March 1, 1996; 27(3): 672 - 678.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
L. E. Rubin and R. Levi
Protective Role of Bradykinin in Cardiac Anaphylaxis : Coronary-Vasodilating and Antiarrhythmic Activities Mediated by Autocrine/Paracrine Mechanisms
Circ. Res., March 1, 1995; 76(3): 434 - 440.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. G. Melaragno and G. D. Fink
Enhanced Slow Pressor Effect of Angiotensin II in Two-Kidney, One Clip Rats
Hypertension, February 1, 1995; 25(2): 288 - 293.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.